Baxdrostat

Baxdrostat (brand name BAXFENDY) is an oral selective aldosterone synthase (CYP11B2) inhibitor from AstraZeneca, approved by FDA on May 18, 2026 for uncontrolled hypertension based on two Phase 3 trials: Bax24 in resistant hypertension (24-hour ambulatory blood pressure primary endpoint, 14.0 mmHg placebo-adjusted reduction) and BaxHTN in uncontrolled hypertension (seated SBP primary endpoint, 9.8 mmHg placebo-adjusted reduction) [1][2][3]. The pipeline story extends well beyond hypertension. Three large Phase 3 outcomes trials combine baxdrostat with dapagliflozin (Farxiga, AstraZeneca's multibillion-dollar SGLT2 inhibitor) to test chronic kidney disease progression (NCT06268873, n=2,554), heart failure events and CV death (NCT06677060, n=11,300), and a composite of kidney failure, heart failure, and cardiovascular mortality (NCT06742723, n=5,000) [4][5][6]. Combined enrollment approaches 19,000 patients. The hypertension approval is the foothold. The cardio-renal-metabolic combination program is where the franchise economics live. AstraZeneca is running the same playbook that turned Farxiga from a type 2 diabetes drug into a multi-indication CV/renal franchise: secure a biomarker-based approval, then layer outcomes trials in adjacent organ systems. Baxdrostat plus dapagliflozin is the next iteration of that strategy, and it pits AstraZeneca against Boehringer Ingelheim and Eli Lilly's vicadrostat plus empagliflozin (Jardiance) in a franchise-versus-franchise race.

FDA approved baxdrostat as BAXFENDY on May 18, 2026 under NDA 219878 for hypertension in adults inadequately controlled on other antihypertensive agents [7]. The approval rests on two Phase 3 trials. Bax24 (NCT06168409) was a double-blind, placebo-controlled trial in 326 resistant-hypertension patients on three or more antihypertensives; primary endpoint was change from baseline in 24-hour ambulatory systolic blood pressure at Week 12. Bax24 delivered a 14.0 mmHg placebo-adjusted reduction in 24-hour ambulatory SBP (95% CI -17.2 to -10.8, p<0.0001), with secondary seated SBP reduction of 10.3 mmHg [1][2]. BaxHTN (NCT06034743) enrolled uncontrolled-hypertension patients on two or more antihypertensives, with seated SBP at Week 12 as primary endpoint and approximately 9.8 mmHg placebo-adjusted reduction [3]. A separate Phase 3 trial in predominantly Asian populations, BaxAsia (NCT06344104), supplements the global program. While the hypertension indication is now approved, the broader pipeline label still applies to several ongoing Phase 3 outcomes trials in chronic kidney disease and heart failure when combined with dapagliflozin. The CKD progression trial (NCT06268873, n=2,554) is active not recruiting, meaning enrollment has closed and patients are being followed; primary completion is expected in 2027 or 2028 [4]. The HF outcomes trial (NCT06677060, n=11,300) and the renal/CV mortality trial (NCT06742723, n=5,000) are both still recruiting, with readouts likely 2028 or later given the time required to accrue cardiovascular and renal events [5][6]. A Phase 2b albuminuria study (NCT07222917, n=218) is running as a mechanistic bridge between blood pressure effect and kidney protection [8]. No breakthrough therapy, fast track, or accelerated approval designations have been publicly disclosed for the cardio-renal program.

Aldosterone is a hormone produced in the adrenal glands that tells the kidneys to hold onto sodium and water and dump potassium. The net effect raises blood pressure. CYP11B2, also called aldosterone synthase, is the enzyme that makes aldosterone from upstream steroid precursors. Block the enzyme, lower aldosterone, lower blood pressure. The problem that killed earlier aldosterone synthase inhibitors was selectivity. CYP11B1 is the closely related enzyme that makes cortisol, the stress hormone essential for life. Knock that out too and patients develop adrenal insufficiency. Baxdrostat was engineered for high selectivity for CYP11B2 over CYP11B1, which is the chemistry that made the class viable [9]. The mechanism has strong validation from the receptor side: spironolactone and eplerenone (mineralocorticoid receptor antagonists, which block aldosterone's downstream signal) are workhorse drugs for resistant hypertension. Finerenone added cardiovascular and renal outcomes data in diabetic CKD. Hitting aldosterone production upstream should give similar or better effect with fewer off-target hormonal side effects, particularly avoiding the gynecomastia (breast tissue growth in men) and menstrual irregularities seen with spironolactone. UniProt (entry P19099) and Open Targets confirm CYP11B2 loss-of-function variants cause hypoaldosteronism and corticosterone methyloxidase deficiency, establishing on-target biology in humans [10]. Vicadrostat from Boehringer Ingelheim and Eli Lilly is the main competitor with the same mechanism.

Bax24 (NCT06168409) was Phase 3, randomized, double-blind, placebo-controlled, n=326, primary endpoint change from baseline in 24-hour ambulatory systolic blood pressure at Week 12 in patients with treatment-resistant hypertension on three or more medications. The 14.0 mmHg placebo-adjusted reduction is roughly double what most newer antihypertensives deliver, and ambulatory measurement (a worn cuff that takes readings throughout day and night) eliminates the white-coat effect that confounds in-office SBP [1][2]. BaxHTN (NCT06034743) was the companion trial in uncontrolled hypertension on two or more medications, with seated SBP at Week 12 as primary endpoint and a 9.8 mmHg placebo-adjusted reduction [3]. BaxAsia (NCT06344104) extends the safety/efficacy database in Asian populations. The forward-looking program is more ambitious. NCT06268873 (n=2,554, active not recruiting) tests baxdrostat plus dapagliflozin versus dapagliflozin alone for slowing CKD progression measured by eGFR slope (estimated glomerular filtration rate, the standard measure of how efficiently kidneys filter waste from blood; its rate of decline over time is the gold-standard surrogate for kidney failure risk) [4]. NCT06677060 (n=11,300, recruiting) tests the combination against dapagliflozin plus placebo for the composite of HF events or CV death, the kind of hard outcome that drives label expansion and payer uptake [5]. NCT06742723 (n=5,000, recruiting) targets a composite of at least 50% sustained eGFR decline, kidney failure, HF events, or CV death [6]. NCT07222917 (Phase 2b, n=218) uses albuminuria reduction as a mechanistic bridge between blood pressure and renal outcomes [8]. Enrichment strategy across the outcomes trials uses standard CKD risk markers (reduced eGFR, elevated albuminuria thresholds at entry) rather than aldosterone-specific biomarker selection, so the trials are testing population-level benefit, not enriched-responder benefit. The choice of dapagliflozin plus placebo as comparator is appropriate given the cardio-renal trial precedent set by DAPA-CKD and DAPA-HF, where dapagliflozin became standard of care. The design tests whether adding baxdrostat to a strong active comparator produces incremental benefit, a higher bar than placebo alone.

Baxdrostat is FDA-approved (BAXFENDY, 2026-05-15). BioCosm's model estimates a drug's first FDA approval, which has already happened here, so no probability is shown - any current trial is a new-indication study.

The biggest mechanism-based risk is hyperkalemia, meaning high blood potassium. Aldosterone tells the kidney to excrete potassium, so blocking aldosterone production raises serum potassium. Severe hyperkalemia can cause fatal cardiac arrhythmias. Spironolactone, eplerenone, and finerenone all carry hyperkalemia warnings, and combining baxdrostat with dapagliflozin (which has its own renal effects) on top of likely background RAAS blockade (the renin-angiotensin-aldosterone system, the hormone cascade that regulates blood pressure and fluid balance, and the target of ACE inhibitors and ARBs) stacks the risk. The Bax24 hypertension trial managed potassium acceptably in 326 patients, but the larger outcomes trials will test the safety profile in sicker CKD populations where potassium handling is already compromised [1]. Selectivity loss against CYP11B1 at higher exposures is the other on-target concern. Partial cortisol suppression could cause fatigue, low blood pressure under stress, or in extreme cases adrenal crisis. Execution risk is real given trial size. NCT06677060 (n=11,300) and NCT06742723 (n=5,000) are multi-year, event-driven studies across hundreds of sites. AstraZeneca has the operational scale, but slow enrollment, protocol amendments, or unfavorable interim looks could push readouts out 12 to 18 months. Commercial risk in hypertension is substantial: generic ACE inhibitors, ARBs, amlodipine, and thiazide diuretics cost pennies. Even with proven SBP reduction, payer access to a branded fourth-line antihypertensive will hinge on prior-authorization friction and price. Exclusivity window: as a new chemical entity, baxdrostat receives 5-year FDA NCE exclusivity through May 2031, and composition-of-matter patents (originally filed by Roche, transferred via CinCor to AstraZeneca in the 2023 acquisition) are estimated to expire in the mid-2030s, subject to patent term extension; precise expiry has not been independently confirmed here and should be checked against the Orange Book. The real franchise economics depend on the CKD and HF outcomes labels reading positive before exclusivity erodes.

Worth watching closely. Baxfendy's May 2026 hypertension approval, anchored by Bax24's 14.0 mmHg placebo-adjusted reduction in 24-hour ambulatory SBP and BaxHTN's 9.8 mmHg seated SBP reduction, is the appetizer. The cardio-renal outcomes program is the entrée. AstraZeneca is running the Farxiga playbook: secure an approval on a biomarker indication (blood pressure here, glycemic control there), then layer outcomes trials in adjacent organ systems where the mechanistic logic points. AstraZeneca total revenue was approximately $54.1B in FY2025, with the CVRM (cardiovascular, renal, metabolic) franchise the second-largest therapy area behind oncology [12]. The specific data point to watch first is the Phase 2b albuminuria readout from NCT07222917, expected 2027. Albuminuria (protein in the urine) is a validated surrogate for kidney damage and a leading indicator for the larger CKD outcomes trial NCT06268873. If the baxdrostat plus dapagliflozin combination drops albuminuria meaningfully beyond what dapagliflozin alone achieves, the Phase 3 CKD readout becomes substantially more likely to hit. If it doesn't separate, the entire renal outcomes program comes under serious doubt. Competitive context is franchise-level, not just molecule-level: Boehringer Ingelheim and Eli Lilly's vicadrostat is paired with empagliflozin (Jardiance, BI/Lilly's SGLT2 inhibitor) in the EASi-KIDNEY Phase 3 trial (~11,000 CKD patients, full results expected 2028/2029) and the parallel EASi-HF trial in HFpEF, so both programs are stacking within their respective SGLT2 franchises [13]. This makes the race as much a Farxiga vs. Jardiance franchise contest as a baxdrostat vs. vicadrostat molecule contest. First-mover advantage in the aldosterone synthase plus SGLT2 combination niche is genuinely contested. Check back: Q2 to Q3 2027 for the albuminuria data, then again in 2028 for the first CKD progression interim analysis.